10 news items
Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
CGTX
21 May 24
therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTX
7 May 24
with mild-to-moderate dementia with Lewy bodies (DLB) in the Phase 2 SHIMMER study, exceeding our target. In addition, we are preparing
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
CGTX
22 Apr 24
their perspectives on the currently approved immunotherapies for early Alzheimer's disease, including perception of their effectiveness in targeting plaque
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
CGTX
2 Apr 24
biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders
Oppenheimer Maintains Outperform on Cognition Therapeutics, Maintains $9 Price Target
CGTX
27 Mar 24
Oppenheimer analyst Jay Olson maintains Cognition Therapeutics (NASDAQ:CGTX) with a Outperform and maintains $9 price target.
fxigrcjpxyyl60bffwpfiqyg6p4vb abk5btc73q
CGTX
26 Mar 24
measured target engagement in the journal, Translational Neurodegeneration
ga3i4wyymbcqxrt9nzqv5an3eiivqosbkuu9ktl61f47
CGTX
15 Mar 24
, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our
8wsiei8a 5b5v9j0mgnqk23woofcq7u1tmq
BSFC
CGTX
EKSO
15 Mar 24
company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders
uf20tmkhdt4
CGTX
11 Mar 24
in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous
a0tvl5bhtx361
CGTX
6 Mar 24
. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age
- Prev
- 1
- Next